title: Weekly paclitaxel in women age 65 and above with metastatic breast cancer.
abstract: We evaluated therapy with weekly paclitaxel 80 mg/m2 in metastatic breast cancer patients age > or =65. There was a low incidence of serious toxicities, with similar tolerability profiles in younger and older patients. Response rates and overall survival times were comparable in the two age groups (<65 and > or =65). Weekly paclitaxel therapy is a reasonable option for older patients with metastatic breast cancer.
authors.affiliation: Division of Hematology/Oncology, Mayo Clinic, Jacksonville, Florida 32224, USA. perez.edith@mayo.edu
authors.forename: Edith A
authors.initials: EA
authors.lastname: Perez
authors.forename: Charles L
authors.initials: CL
authors.lastname: Vogel
authors.forename: David H
authors.initials: DH
authors.lastname: Irwin
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Kirshner
authors.forename: Ravi
authors.initials: R
authors.lastname: Patel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel; D002955:Leucovorin